R. Chapin

Publications12
h-index1
Citations16
Highly Influential Citations1
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Dorr
  • 73 Publications • 2,009 Citations
  • D. Guris
  • 59 Publications • 4,838 Citations
  • C. Kelly
  • 482 Publications • 29,009 Citations
  • M. Wilcox
  • 690 Publications • 35,062 Citations
  • Publications
  • Influence
Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
TLDR
In patients treated with SoC antibiotics, BEZ is effective in decreasing rCDI, and the greatest benefit has been demonstrated in high-risk patients, though the targeted patient population is yet to be defined.
View on SAGE
Restriction-free antimicrobial stewardship initiative targeting fluoroquinolone reduction across a regional health-system
View on PubMed
Assessment of a Healthcare-Associated Pneumonia (HCAP) Risk Stratification and Empiric Treatment Guideline: A New Antimicrobial Stewardship Initiative
TLDR
Introduction of a risk stratified guideline through AST intervention changed practice by matching MDR risk with empiric HCAP therapy and decreased MDR GN antimicrobial use in low-risk patients.
View PDF
Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 2: Answers to questions about Epoetin alfa.
View on PubMed
1092. Impact of Relieving Infectious Diseases Fellows from Off-Hour/Weekend Antimicrobial Stewardship Coverage
TLDR
Relieving IDFs of evening and weekend ASP coverage during busy inpatient consult rotations may help decrease burnout and was associated with a relative decrease in piperacillin–tazobactam, meropenem, and vancomycin use.
View PDF
228. Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm Risk
TLDR
Inpatient fluoroquinolone prescribing for DFI decreased significantly following the 2018 FDA Communication, followed by an increase in antipseudomonal beta-lactam use and Outpatient Parenteral Antibiotic Therapy (OPAT) enrollment.
View via Publisher
54. Microbiologic Characterization and Antibacterial Use in Hospitalized Adults with covid-19 Infection
TLDR
Bacterial co-infection in an acute viral process is generally low in CoVID-19 infected patients, and a disproportionate effect on the volume of antibiotics and total days of therapy prompted an interest in early stewardship efforts and education.
View via Publisher
Grading the Impact of a Standardized Β Lactam Antibiotic Allergy Assessment Protocol for Treatment Decisions: An Antimicrobial Stewardship Target
TLDR
Introduction of a multidisciplinary guideline by AST and Allergy led to preferred utilization of graded challenge over full ICU desensitization and an overall decrease in aztreonam use.
View PDF
Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm Risk
TLDR
This quasi-experimental study assessed antibiotic prescribing for 198 hospitalized patients with diabetic foot infection and found that following the warning, median inpatient fluoroquinolone days of therapy decreased, corresponding with increased beta-lactam DOT and OPAT enrollment.
View on ASMUSA
Diminishing returns, increasing risks: Impact of antibiotic duration of therapy on respiratory bacterial isolates in hospitalized patients during the coronavirus disease 2019 (COVID-19) pandemic
Abstract In 829 hospital encounters for patients with COVID-19, 73.2% included orders for antibiotics; however, only 1.8% had respiratory cultures during the first 3 hospital days isolating bacteria.…
View on Cambridge Press
...
...